Concepedia
Statistics
Publications
16
Citations
1.1K
H-Index
14
Active since
1995
Affiliations
National Cancer Research Institute(Current)
Nara Medical University
Vanderbilt University
National Cancer Centre Japan
Tokushima University
Hirokazu Kurokawa is an author at National Cancer Research Institute specializing in oncology, medicine, and molecular oncology.
Publications per year
1995–2004
Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells.
Hirokazu Kurokawa, Anne E.G. Lenferink, Jean F. Simpson et al. · PubMed · 2000 · 367 citations
Medicine, Cancer Biology, Oncology +16
Conditional Overexpression of Active Transforming Growth Factor β1 <b> <i>In vivo</i> </b> Accelerates Metastases of Transgenic Mammary Tumors
Rebecca S. Muraoka-Cook, Hirokazu Kurokawa, Yasuhiro Koh et al. · Cancer Research · 2004 · 159 citations · Full text
ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms.
Hirokazu Kurokawa, Carlos L. Arteaga · PubMed · 2003 · 140 citations
Life Sciences, Molecular Biology, Oncology +17
Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
Hirokazu Kurokawa, Carlos L. Arteaga · PubMed · 2001 · 94 citations
Life Sciences, Biochemistry, Oncology +17
Enhanced interaction between tubulin and microtubule‐associated protein 2 via inhibition of MAP kinase and CDC2 kinase by paclitaxel
Kazuto Nishio, Hitoshi Arioka, Tomoyuki Ishida et al. · International Journal of Cancer · 1995 · 54 citations
Medicine, Oncology, Pharmacology +12
1–5 of 16